THOMAS M. BRAUN - U-M School of Public Health · THOMAS M. BRAUN EDUCATION September 1996 – July 1999 University of Washington, Seattle, Washington Ph.D., Biostatistics

Last Updated: May 11, 2016 Page 1

U N I V E R S I T Y O F M I C H I G A N • D E P A R T M E N T O F B I O S T A T I S T I C S • M 4 0 6 3 S P H I I • 1 4 1 5 W A S H I N G T O N H E I G H T S • A N N A R B O R , M I 4 8 1 0 9 - 2 0 2 9

P H O N E ( 7 3 4 ) 9 3 6 - 9 8 4 4 • F A X ( 7 3 4 ) 7 6 3 - 2 2 1 5 • E - M A I L T O M B R A U N @ U M I C H . E D U

T H O M A S M . B R A U N

EDUCATION

September 1996 – July 1999 University of Washington, Seattle, Washington

Ph.D., Biostatistics n Dissertation Title: “Weighted Permutation Tests for the Analysis of Group

Randomized Trials”

September 1994 – July 1996 University of Washington, Seattle, Washington

M.S., Biostatistics

September 1986 – May 1990 University of Wisconsin, Madison, WI

B.B.A., Actuarial Science

PROFESSIONAL EXPERIENCE Professor

September 2012 – present University of Michigan, Ann Arbor, Michigan

Associate Professor

September 2008 – August 2012 University of Michigan, Ann Arbor, Michigan

Assistant Professor

September 2005 – August 2008 University of Michigan, Ann Arbor, Michigan

Assistant Research Professor

August 1999 – August 2005 University of Michigan, Ann Arbor, Michigan

Senior Actuarial Assistant

July 1990 – July 1994


Metropolitan Life Insurance Company, Mt. Prospect, Illinois

AWARDS Highest Rated Lecture, ASCO/AACR Methods in Clinical Cancer Research Workshop,

July 2015.

Clinical Research Award for Most Influential Manuscript of 2014, American Academy of Periodontology, September 2014

Senior Biostatistics Student Award, University of Washington, Seattle, WA, Spring 1999

Outstanding Biostatistics Student Scholarship, University of Washington, Seattle, WA, Winter 1998

Best Oral Presentation in WNAR Student Papers Competition, Summer 1998

NIH Predoctoral Cancer Prevention Training Grant, FHCRC, Seattle, WA, September 1996 to July 1999

INTERNAL PROFESSIONAL SERVICE Chair, Admissions Committee, University of Michigan Biostatistics Department,

September 2014-August 2015.

Member, Executive Committee, University of Michigan School of Public Health, January 2014-May 2014 & September 2015-present.

Member, Faculty Search Committee, University of Michigan Biostatistics Department, September 2009-August 2011.

Member, Admissions Committee, University of Michigan Biostatistics Department, September 2005-August 2009; September 2012-August 2014; September 2015-present.

Member, Ph.D. Candidacy Committee, University of Michigan Biostatistics Department, September 2005-August 2006 & September 2008-August 2009.

Chair, Ph.D. Candidacy Committee, University of Michigan Biostatistics Department, September 2009-August 2010.

Member, Protocol Review Committee, University of Michigan Comprehensive Cancer Center, September 1999-August 2005; August 2009-August 2011; September 2015-present.

Biostatistician, University of Michigan General Clinical Research Center, January 2006-May 2006.

Resolution Officer, Office of Student Conflict Resolution (OSCR), University of Michigan, November 1999-November 2001.

Faculty Advisor for Michigan Student Symposium of Integrated Statistical Sciences


(MSSISS) September 2009 to June 2011.

EXTERNAL PROFESSIONAL SERVICE Faculty Member, AACR/ASCO Methods in Clinical Cancer Research Workshop.

Summer 2013, 2014, & 2015. Faculty Member, ASBMT Clinical Research Training Course. Summer 2014 , 2015, and 2016.

Associate Editor, Biometrics, July 2010-present.

Member, Regional Advisory Board for Eastern North American Region (ENAR) of the Biometrics Society, 2010-2013.

Member, Biostatistics Track Submitted Abstract Review Panel, American Society of Clinical Oncology (ASCO), 2010-2012.

Ad-Hoc Reviewer for NIDCR Scientific Review Group, 2009-2010.

Ad-Hoc Reviewer for Veterans Administration Scientific Review Group, 2009-2010.

Ad-Hoc Reviewer for NIH Special Emphasis Panel/Scientific Review Groups, 2002-2006.

Member of Data Safety Monitoring Board for Hoosier Oncology Group, 2006.

Manuscript Referee for: American Journal of Clinical Oncology American Statistician Annals of Applied Statistics Annals of Epidemiology Biometrics Biometrical Journal Clinical Cancer Research Clinical Diabetes and Endocrinology (Editorial Board Member) Clinical Trials Encyclopedia of Clinical Trials Fundamental & Clinical Pharmacology Genomics Haematologica International Journal of Biostatistics JAMA Oncology Journal of the American Statistical Association Journal of Bone and Mineral Research Journal of Clinical Epidemiology Journal of Dental Research Journal of Probability and Statistics Journal of Periodontology Journal of Statistical Planning and Inference Lifetime Data Analysis Metrika Nicotine & Tobacco Research


Pediatric Blood & Cancer Psychological Reports: Perceptual and Motor Skills Statistics in Biopharmaceutical Research Statistics In Medicine Therapeutic Innovation & Regulatory Science

PRESENTATIONS Invited Presentation, “The Bivariate CRM: Extending the CRM to Phase I Trials of

Two Competing Outcomes.” Fall 2001, Columbia University. Contributed Presentation, “A Parametric Bootstrap Method for Comparing Cumulative Incidence with Competing Risks.” Spring 2002, ENAR Annual Conference. Invited Presentation, “Determining a Maximal Period of Administration for an Experimental Agent.” Spring 2004, ENAR Annual Conference. Invited Presentation, “Determining a Maximal Period of Administration for an Experimental Agent.” Spring 2005, MD Anderson Cancer Center. Invited Presentation, “Determining a Maximal Period of Administration for an Experimental Agent.” Summer 2005, BASS XII Conference, Georgia Southern University. Invited Presentation, “Determining a Maximal Period of Administration for an Experimental Agent.” Summer 2006, International Chinese Statistical Association (ICSA) Annual Conference. Contributed Presentation, “Simultaneously Optimizing Dose and Schedule of a New Cytotoxic Agent.” Summer, 2006, IBS Annual Conference. Contributed Presentation, “An Alternative Approach to Permutation Tests for Comparing Correlated ROC Curves.” Spring 2007, ENAR Annual Conference. Invited Presentation, “Simultaneously Optimizing Dose and Schedule of a New Cytotoxic Agent.” Summer, 2007, WNAR Annual Conference. Invited Presentation, “A Hierarchical Bayesian Design for Phase I Trials of Novel Combinations of Cancer Therapeutic Agents.” Summer, 2007, JSM Annual Conference. Invited Presentation, “Parametric Approaches for Optimizing Treatment Schedules in Adaptive Early-Phase Clinical Trials.” Fall, 2007, Vanderbilt University Department of Biostatistics. Invited Presentation, “Parametric Approaches for Optimizing Treatment Schedules in Adaptive Early-Phase Clinical Trials.” Winter, 2008, Johns Hopkins University Department of Biostatistics. Invited Presentation, “Parametric Approaches for Optimizing Treatment Schedules in Adaptive Early-Phase Clinical Trials.” Winter, 2008, University of Minnesota Department of Biostatistics. Invited Presentation, “Parametric Approaches for Optimizing Treatment Schedules in


Adaptive Early-Phase Clinical Trials.” Fall, 2009, University of Iowa Department of Biostatistics. Invited Presentation, “Parametric Approaches for Optimizing Treatment Schedules in Adaptive Early-Phase Clinical Trials.” Fall, 2008, University of Michigan Department of Biostatistics. Invited Presentation, “Incorporating Patient Heterogeneity in Adaptive Phase I Trial Designs.” Fall, 2009, Conference on CRM and Related Methods for Phase I Study Designs. Contributed Presentation, “A Hierarchical Bayesian Design for Phase I Trials of Novel Combinations of Cancer Therapeutic Agents.” Winter 2010, MD Anderson Cancer Center Bayesian Biostatistics Conference. Invited Presentation, “Permutation Tests for Random Effects in Linear Mixed Models.” Spring, 2011, ENAR Annual Conference. Invited Presentation, “Bayesian Adaptive Designs for Identifying Maximum Tolerated Combinations of Two Agents.” Summer 2012, Design of Experiments in Healthcare Conference, Issac Newton Institute. Invited Presentation, “Adaptive Prior Variance Calibration in the Bayesian Continual Reassessment Method.” Fall, 2011, Workshop on CRM and Related Methods for Phase I Study Designs. Invited Presentation, “A Generalized Continual Reassessment Method for Two-Agent Phase I Trials.” Winter, 2012, MD Anderson Cancer Center. Invited Presentation, “The Bayesian Continual Reassessment Method Using a Mixture-of-Uniforms Prior.” Summer, 2012, JSM Annual Conference. Invited Presentation, “Modeling the Distribution of Periodontal Disease with a Generalized von Mises Distribution.” Spring 2013, ENAR Annual Conference. Invited Presentation, “Statistical Concepts in OMS Clinical Trials.” Fall, 2013, ICOMS Annual Conference. Invited Presentation, “Designing Early Phase Clinical Trials: Where We Are is Not Where We Should Be.” Winter, 2014, ASBMT Annual Tandem Meeting. Panel Member, “Having It All: Weighting To Achieve Balance.” Spring 2014, ENAR Annual Conference. Invited Presentation, “Motivating Sample Size in One- and Two-Agent Phase I trials via Bayesian Posterior Credible Intervals.” Fall 2014, University of Wisconsin-Madison. Invited Presentation, “Motivating Sample Size in One- and Two-Agent Phase I trials via Bayesian Posterior Credible Intervals.” Fall 2014, Workshop on CRM and Related Methods for Phase I Study Designs.


Invited Presentation, “Motivating Sample Size in One- and Two-Agent Phase I trials via Bayesian Posterior Credible Intervals.” Spring 2015, ENAR Annual Conference. Invited Presentation, “Using Patient Samples to Predict Periodontal Disease Progression.” Spring 2016, Annual Spring Meeting of Task Force on Design and Analysis in Oral Health Research. Invited Presentation, “The Utility of Conditional Autoregressive (CAR) Models for Modeling Efficacy of Molecularly Targeted Agents in Early-Phase Trials, Winter 2016, University of Pennsylvania. Invited Presentation, “The Utility of Conditional Autoregressive (CAR) Models for Modeling Efficacy of Molecularly Targeted Agents in Early-Phase Trials, Summer 2016, JSM Annual Conference.

PROFESSIONAL MEMBERSHIPS American Statistical Association, April 2000 to present

International Biometric Society, April 1998 to present

Society of Actuaries, Associate, August 1992 to January 1996

TEACHING EXPERIENCE Biostatistics 503: Introduction to Biostatistics

n Fall 2000, Fall 2014 n Taught to first-year School of Public Health graduate students. n Covered descriptive statistics, probability, statistical inference, simple linear

regression, ANOVA, and χ2-tests. Biostatistics 523: Biomedical Methods for Health Related Studies n Winter 2003 n Taught to first-year School of Public Health graduate students. n Covered linear regression, ANOVA, logistic & Poisson regression. Biostatistics 560: Statistical Methods for Epidemiology n Fall 2010 n Taught to cohort of medical investigators seeking additional education on clinical

trial design and data analysis. n Covered theory and SAS applications of contingency table and regression methods

for matched and unmatched case/control and cohort studies. n Covered theory and SAS applications for censored time-to-event data. Biostatistics 560 (OJ/OC): Statistical Methods for Epidemiology n July 2006 – April 2007 & August 2008 – March 2009 (monthly lectures) n Taught to cohort of medical investigators seeking additional education on clinical

trial design and data analysis.


n Covered theory and SAS applications of contingency table and regression methods for matched and unmatched case/control and cohort studies.

n Covered theory and SAS applications for censored time-to-event data. Biostatistics 619: Clinical Trials n Fall 2007, Fall 2008, Fall 2009, Fall 2012, and Fall 2013 n Taught to Masters’ level Biostatistics students. n Covered design issues related to Phase I, Phase II, and Phase III clinical trials. Biostatistics 653: Applied Statistics III – Correlated Data Methods n Winter 2004, Winter 2005, Winter 2007, & Winter 2008 n Taught to Masters’ level Biostatistics students. n Covered theory and SAS application of MANOVA, linear mixed models, and

generalized estimating equations. Biostatistics 685: Nonparametric Methods n Winter 2002, Winter 2002, Winter 2006, Winter 2010, & Winter 2011. n Taught to Masters’ level Biostatistics students. n Covered theory and application of rank tests, resampling techniques and smoothing

techniques.

Biostatistics 699: Design and Analysis of Biostatistical Investigations n Winter 2013 & Winter 2014 n Taught to Masters’ level Biostatistics students. n Capstone course designed to give students the opportunity to analyze real data and

develop skills necessary for collaborative relationships with investigators. Biostatistics 601: Probability & Distribution Theory n Fall 2015, Fall 2016 n Taught to primarily Masters’ level Biostatistics students. n First semester of a two-semester sequence in probability and statistics; covers first

five chapters of Casella & Berger. Biostatistics 810: Approaches to the Responsible Practice of Biostatistics n Fall 2015, Fall 2016 n Taught to primarily first-year Ph.D. Biostatistics students. n One-credit course developed to cover a series of topics that encompass (1)

Responsible Conduct of Research and Scholarship (RCRS) as mandated by the UM Rackham Graduate School, and (2) developing the oral and written communication skills necessary for successful collaborations with public health investigators.

PHD DISSERTATIONS ADVISED


Changying Angela Liu, 2007, “Parametric Models for Optimal Treatment Schedule Finding in Adaptive Early-Phase Clinical Trials”

Philip Westgate, 2011, “Improving Small-Sample Inference in Group Randomized Trials and Other Sources of Correlated Binary Data”

Nan Jia, 2012, “Generalized Statistical Approaches for the Design for Phase I Trials”

Samopriyo Maitra, 2012, “Applications of Circular Distributions and Spatial Point Processes to the Analysis of Periodontal Data”

Oliver Lee, 2012, “Permutation Tests for Random Effects in Mixed Models”

Jin Zhang, 2013, “Methods for Identifying Optimal Dose and Schedule Assignments in Phase I Clinical Trials”

Su Chen, 2013, “Estimation and Inference Methods for Pooled Longitudinal Correlation Coefficients”

Shan Kang, 2014, “Treatment Effect Estimation for Randomized Clinical Trials Subject to Noncompliance and Missing Outcomes” (co-advisor with Rod Little)

Rong Xia (co-advisor with Mousumi Banerjee), dissertation in progress

Zichao Sun (co-advisor with Bhramar Mukerjee), dissertation in progress

Daniel Muenz (co-advisor with Jeremy Taylor), dissertation in progress

Yumeng Li, dissertation in progress

Brian Segal, dissertation in progress

Boxian Wei, dissertation in progress

PEER-REVIEWED PUBLICATIONS Murphy SA, Braun TM, Tillery L, Cain KC, Johnson C, Beaton RD. PTSD Among

Bereaved Parents Following the Violent Deaths of Their 12 to 28 Year-old Children: A Longitudinal Prospective Analysis. Journal of Traumatic Stress. (12): 273-291, 1999.

Murphy SA, Lohan J, Braun TM, Johnson LC, Cain KC, Baugher R, Beaton R. Parents’ Health, Health Care Utilization, and Health Behaviors Following the Violent Deaths of Their 12 to 28 Year-old Children: A Prospective Longitudinal Analysis. Death Studies. (23): 589-616, 1999.

Reynolds C, Ratanatharathorn V, Adams P, Braun T, et al. Allogeneic Stem Cell Transplantation Reduces Disease Progression Compared to Autologous Transplantation in Patients with Multiple Myeloma. Bone Marrow Transplantation. (27): 801-807, 2001.

Ayash L, Clarke M, Silver S, Braun T, Uberti J, Ratanatharathorn V, Reynolds C, Ferrara J, Broun R, Adams P. Double Dose-Intensive Chemotherapy with Autologous Stem Cell Support for Relapsed and Refractory Testicular Cancer: The University of Michigan Experience and Literature Review. Bone Marrow Transplantation. (27): 939-947, 2001.

Kleer C, Van Golen K, Braun T, Merajver, S. Persistent E-Cadherin Expression in Inflammatory Breast Cancer. Modern Pathology. (5): 458-464, 2001.

Kleer C, Giordano T, Braun T, Oberman H. Pathologic, Immunohistochemical, and


Molecular Features of Benign and Malignant Phyllodes Tumors of the Breast. Modern Pathology. (3): 185-190, 2001.

Braun T, Feng Z. Optimal Permutation Tests for the Analysis of Group Randomized Trials. Journal of the American Statistical Association (96): 1424-1432, 2001.

Geiger J, Hutchinson R, Hohenkirk L, McKenna E, Yanik G, Levine J, Chang A, Braun T, Mulé J. Vaccination of Pediatric Solid Tumors with Tumor Lysate-Pulsed Dendritic Cells Expand Specific T Cells and Mediates Tumor Regression. Cancer Research (61): 8513-8519, 2001.

Levine J, Braun T, Penza S., et al. A Prospective Trial of Chemotherapy and Donor Leukocyte Infusions for Relapse of Advanced Myeloid Malignancies Following Allogeneic Stem Cell Transplantation. Journal of Clinical Oncology (20):405-412, 2002.

Yanik G, Matthay K, Levine J, Sisson J, Shulkin B, Shapiro B, Hubers D, Spalding S, Braun T, Ferrara J, Hutchinson, R. Pilot Study of I-Meta-iodobenzylguanidine in Combination with Myeloablative Chemotherapy and Autologous Stem Cell Support for the Treatment of Neuroblastoma. Journal of Clinical Oncology (20): 2142-2149, 2002.

Chang A, Redman B, Whitfield J, Nickoloff B, Braun T, et al. A Phase I Trial of Tumor Lysate Pulsed Dendritic Cells in the Treatment of Advanced Cancer. Clinical Cancer Research (8): 1021-1032, 2002.

Braun TM. The Bivariate CRM: Extending the CRM to Phase I Trials of Two Competing Outcomes. Controlled Clinical Trials (23): 240-255, 2002.

Ordemann R, Hutchinson R, Friedman J, Burakoff SJ, Reddy P, Duffner U, Braun TM, Liu C, Teshima T, Ferrara JLM. Enhanced Allostimulatory Activity of Host Antigen-Presenting Cells in Old Mice Intensifies Acute Graft-versus-Host Disease. Journal of Clinical Investigation (109):1249-1256, 2002.

Campbell BT, Braun TM, Schumacher RE, Bartlett RH, Hirschl, RB. Impact of ECMO on Neonatal Mortality in Michigan (1980-1999). Journal of Pediatric Surgery (38): 290-295, 2003.

Levine JE, Uberti JP, Ayash LA, Reynolds C, Ferrara JLM, Silver SM, Braun T, Yanik G, Hutchinson R, and Ratanatharathorn, V. Lowered Intensity Preparative Regimen for Allogeneic Stem Cell Transplantation Delays Acute GVHD But Does Not Improve Outcome for Advanced Hematologic Malignancy. Biology of Blood and Marrow Transplantation (10): 189-197, 2003.

Chang AE, Li Q, Jiang G, Sayre D, Braun TM, Redman BG. A Phase II Trial of Autologous Tumor Vaccination, Anti-CD3 Activated Vaccine-Primed Lymphocytes Plus IL-2 in Stage IV Renal Cell Cancer. Journal of Clinical Oncology (21): 884-890, 2003.

Braun TM, Levine JE, Ferrara JLM. Determining a Maximum Tolerated Cumulative Dose: Dose Reassignment Within the TITE-CRM. Controlled Clinical Trials (24): 669-681, 2003.

Braun TM. A Mixed Model Formulation for Designing Cluster Randomized Trials


with Binary Outcomes. Statistical Modelling (3): 233-249, 2003.

Braun TM. Feng, Z. Identifying Settings When Permutation Tests are Nominal with Paired, Binary-Outcome, Group Randomized Trials. Journal of Nonparametric Statistics (15): 653-663, 2003.

Alonzo TA, Braun TM, Moskowitz CS. Small Sample Estimation of Relative Accuracy for Binary Screening Tests. Statistics in Medicine (23): 21-34, 2004.

Uberti JP, Ayash L, Braun T, Reynolds C, Silver S, Ratanatharathorn, V. Tacrolimus as Monotherapy or Combined with Minidose Methotrexate for Graft-versus-Host Disease Prophylaxis After Allogeneic Blood Stem Cell Transplantation: Long-Term Outcomes. Bone Marrow Transplantation (34): 425-431, 2004.

Braun TM, Yuan Z, Thall PF. Determining a Maximum Tolerated Schedule of a Cytotoxic Agent. Biometrics (61): 335-343, 2005.

Alexander BM, Wechsler D, Herman J, Braun TM, Yanik G, Hutchinson R, Levine J, Pierce LJ. Role of Cranial Boost in Addition to Total Body Irradiation in the Treatment of High Risk Acute Lymphoblastic Leukemia. International Journal of Radiation Oncology, Biology, and Physics (63): 1191-1196, 2005.

Hughes DPM, Baskar D, Urban FA, Friedman MS, Braun TM, McDonagh KT. Fate and Function of Anti-CD3/CD28 Activated T Cells Following Adoptive Transfer: IL-2 Promotes Development of Antitumor Memory T Cells In Vivo. Cytotherapy (7): 396-407, 2005.

Uberti J, Ayash L, Ratanatharathorn V, Silver S, Reynolds C, Becker M, Reddy P, Cooke KR, Yanik G, Whitfield J, Jones D, Hutchinson R, Braun T, Ferrara JLM, Levine, JE. Pilot Trial on the Use of Etanercept and Methylprednisolone as Primary Treatment for Acute Graft-vs-Host Disease (aGVHD) Biology of Blood and Marrow Transplantation (11): 680-687, 2005.

Braun TM. Generalizing the TITE-CRM to Adapt for Early- and Late-Onset Toxicities. Statistics in Medicine (25): 2071-2083, 2006. MacGregor, JN, Li Q, Chang AE, Braun TM, Hughes DPH, McDonagh KT. Ex vivo Culture with IL-12 Improves CD8+ T Cell Adoptive Immunotherapy for Murine Leukemia Independent of IL-18 or IFN*, but Requires Perforin. Cancer Research (66): 4913-4921, 2006. Taylor JMG, Braun TM, Li Z. Comparing an Experimental Agent to a Standard Agent: Relative Merits of a One-Arm or Randomized Two-Arm Phase II Design. Clinical Trials (3): 335-348, 2006. Blazar BR, Weisdorf DJ, DeFor TE, Goldman A, Braun T, Silver S, Ferrara JLM. A Phase I/II Randomized, Placebo-Control Trial of Palifermin to Prevent Graft-Versus-Host Disease (GVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). Blood (108): 3216-3222, 2006. Reddy P, Johnson K, Uberti JP, Reynolds C, Silver S, Ayash L, Braun TM, Ratanatharathorn V. Nephrotic Syndrome associated with Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation. Bone Marrow


Transplantation (38):351-357, 2006. Braun TM, Yuan Z. Comparing the Small Sample Performance of Several Variance Estimators under Competing Risks. Statistics in Medicine (26): 1170-1180, 2007.

Saraiva MCP, Thaichman RS, Braun TM, Nriagu J, Eklund SA, Burt BA. Lead Exposure and Periodontitis: A Cross-Sectional Study. Journal of Periodontal Research (42): 45-52, 2007. Braun TM, Thall PF, Nguyen H, de Lima M. Simultaneously Optimizing Dose and Schedule of a New Cytotoxic Agent. Clinical Trials (4): 113-124, 2007. Braun TM. A Mixed Model-Based Variance Estimator for Marginal Model Analysis of Cluster Randomized Trials. Biometrical Journal (49): 394-405, 2007. Stender RN, Engler, WJP, Braun TM, Hankenson, C. Establishment of Blood Analyte Intervals for Laboratory Mice and Rats Using the i-STAT ® Portable Clinical Analyzer. Journal of the American Association for Laboratory Animal Science (46): 47-52, 2007. Sleight BS, Chan KW, Braun TM, Serrano, A, Gilman AL. Infliximab for GVHD Therapy in Children. Bone Marrow Transplantation (40): 473-480, 2007. Wasco MJ, Daignault S, Zhang Y, Kunju, LP, Kinnaman M, Braun T, Lee, CT, Shah RB. Urothelial Carcinoma with Divergent Histological Differentiation (Mixed Histology) is an Independent Predictor of Presence of Extravesical Tumor when Detected at Transurethral Resection. Urology (70): 69-74, 2007. Peres, E, Abidi MH, Mellon-Reppen S, Klein J, Braun T, Abella E, Dansey, R. Reduced Intensity Transplantation for Metastatic Renal Cell Cancer With 2-year Follow-up. Journal of Immunotherapy (30): 562-566, 2007. Levine JE, Paczesny S, Mineishi S, Braun T, et al. Etanercept Plus Methyl-prednisolone as Initial Therapy for Acute GVHD. Blood (111): 2470-2475, 2008. Braun TM, Alonzo TA. A Modified Sign Test for the Comparison of Paired ROC Curves. Biostatistics (9): 364-372, 2008. Nease DE, Ruffin MT, Jimbo M, Klinkman MS, Braun TM, Underwood J. Impact of a Generalizable Reminder System on Colorectal Cancer Screening in Diverse Primary Care Practices: A Report From the Prompting and Reminding at Encounters for Prevention Project. Medical Care (46): S68-S73, 2008. Brubaker L, Richter HE, Visco A, Mahajan S, Nygaard I, Braun TM, Barber MD, Menefee S, Schaffer J, Weber AM, Wei J. Refractory Idiopathic Urge Urinary Incontinence and Botulinum A Injection. Journal of Urology (112): 217-222, 2008. Choi SW, Kitko CL, Braun T, et al. Change in Plasma Tumor Necrosis Factor Receptor 1 Levels in the First Week Post-Myeloablative Allogeneic Transplant Correlates with Severity and Incidence of GVHD and Survival. Blood (112): 1539-1542, 2008.


Kitko CL, Paczensny S, Yanik G, Braun T, Jones D, Whitfield J, Choi S, Hutchinson RJ, Ferrara JLM, Levine JE. Plasma Elevations of Tumor Necrosis Factor-Receptor-1 at Day 7 Post Allogeneic Transplant Correlate with Graft Versus Host Disease Severity and Overall Survival in Pediatric Patients. Biology of Blood and Marrow Transplantation (14): 759-765, 2008. Yanik GA, Ho VT, Levine J, White ES, Braun T, Antin J, Whitfield J, Custer J, Jones D, Ferrara JLM, Cooke KR. The Impact of Soluble Tumor Necrosis Factor Receptor: Etanercept on the Treatment of Idiopathic Pneumonia Syndrome Following Allogeneic Hematopoietic Stem Cell Transplantation. Blood (112): 3073-308, 2008. Redman BG, Chang AE, Whitfield J, Esper P, Jiang G, Braun T, Roessler B, Mule JJ. Phase Ib Trial Assessing Autologous, Tumor-Pulsed Dendritic Cells as a Vaccine Administered With or Without IL-2 in Patients with Metastatic Melanoma. Journal of Immunotherapy (31): 591-598, 2008. Paczesny S, Levine J, Braun TM, Ferrara, JLM. Plasma Biomarkers in GVHD: A New Era? Biology of Blood and Marrow Transplantation (15): 33-38, 2009. Peres E, Braun T, Krijanovski O, Khaled Y, Levine JE, Yanik G, KatoK, Mineishi S. Reduced Intensity Versus Full Myeloablative Stem Cell Transplant for Advanced CLL. Bone Marrow Transplantation (44): 579–583, 2009. Paczesny S, Krijanovski O, Braun TM, et al. A biomarker panel for acute graft versus host disease. Blood (113): 273-278, 2009. Gapski R, Hasturk H, Van Dyke TE, Oringer, RJ, Wang S, Braun TM, Giannobile WV. Systemic MMP Inhibition Promotes Periodontal Wound Repair: Results of a Multi-Center Randomized Controlled Clinical Trial. Journal of Clinical Periodontology (36): 149-156, 2009. Ramseier CA, Kinney JS, Herr AE, Braun T, Sugai JV, Shelburne CA, Rayburn LA, Tran HM, Singh AK, Giannobile WV. Identification of Pathogen and Host-Response Markers Correlated with Periodontal Disease. Journal of Periodontology (80): 436-446, 2009. Liu CA, Braun TM. Parametric Non-Mixture Cure Models for Schedule Finding of Therapeutic Agents. Journal of the Royal Statistical Society, Series C: Applied Statistics (58): 225-236, 2009. Jakubowiak AJ, Kendall T, Al-Zoubi A, Khaled Y, Mineishi S, Ahmed A, Campagnaro E, Brozo C, Braun T, Talpaz M, Kaminski MS. Phase II Trial of Combination Therapy with Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone (VDD) in Patients with Newly Diagnosed Myeloma. Journal of Clinical Oncology (27): 5015:5022, 2009. Salvi GE, Franco LM, Braun TM, Lee A, Rutger Persson G, Lang NP, Giannobile WV. Pro-Inflammatory Biomarkers During Experimental Gingivitis in Patients with Type 1 Diabetes: A Proof-of-Concept Study. Journal of Clinical Periodontology (37): 9–16, 2010. Braun TM, Wang SA. Hierarchical Bayesian Design for Phase I Trials of Novel


Combinations of Cancer Therapeutic Agents. Biometrics (66): 805-812, 2010. Pazcesny S, Braun TM, et al. Elafin Is a Biomarker of Graft-Versus-Host Disease of the Skin. Science Translational Medicine (2): 1-8, 2010. Magenau, JM, Qin X, Tawara I, Rogers CE, Kitko C, Schlough M, Bickley D, Braun TM, et al. Frequency of CD4+CD25hiFOXP3+ Regulatory T Cells Has Diagnostic and Prognostic Value as a Biomarker for Acute Graft-Versus-Host-Disease. Biology of Blood and Marrow Transplantation (16): 907-914, 2010. Avila-Ortiz G, Wang H-L, Galindo-Moreno P, Misch CE, Bagramian RA, Rudek I, Benavides E, Moreno-Riestra I, Braun T, Neiva R. The Influence of the Bucco-Palatal Distance on Sinus Augmentation Outcomes. Journal of Periodontology (81): 1041-1050, 2010. Bashutski JD, Eber R, Kinney J, Benavides E, Maitra S, Braun TM, Giannobile WV, McCauley LK. Teriparatide Promotes Osseous Regeneration in the Oral Cavity. New England Journal of Medicine (363): 2396-2405, 2010. De Lima M, Giralt S, Thall PF, de Padua Silva L, Popat U, Hosing C, Wang X, Shpall EJ, Jones RB, Qazilbash M, McCormick G, Andersson BS, Komanduri K, Alousi A, Gulbis A, Braun TM, Nguyen HQ, Kebriaei P, Champlin R, Garcia-Manero G. Maintenance Therapy with Low-Dose Azacitidine after Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed AML or MDS: a Dose and Schedule Finding Study. Cancer (116): 5420-5431, 2010. Peters MC, Tallman JA, Braun TM, and Jacboson JJ. Clinical Reduction of S. mutans in Pre-School Children after Use of a Novel Licorice Root Lollipop. European Academy of Paediatric Dentistry (11): 274-278, 2010. Song L, Northouse, LL, Braun TM, Zhang L, Cimprich B, Ronis D, Mood, D. Assessing Longitudinal Quality of Life in Prostate Cancer Patients and Their Spouses: A Multilevel Modeling Approach. Quality of Life Research (20): 371–381, 2011. Westgate PM, Braun TM. Improving Small-Sample Inference in Group Randomized Trials with Binary Outcomes. Statistics in Medicine (30): 201-210, 2011. Murdoch-Kinch, CA, Russo N, Griffith S, Braun T, Eisbruch A, D’Silva NJ. Recovery of Salivary EGF in Parotid Saliva Following Parotid Sparing Radiation Therapy: A Proof of Principle Study. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology (11): 64-70, 2011. Song L, Northouse L, Zhang L, Braun T, Cimprich B, Ronis D, Mood D. Study of Dyadic Communication in Couples Managing Prostate Cancer: A Longitudinal Perspective. Psycho-Oncology (20): 72-81, 2011. Morelli T, Neiva R, Nevins ML, McGuire MK, Scheyer ET, Oh T-J, Braun TM, Nor JE, Bates D, Giannobile WV. Angiogenic Biomarkers and Healing of Living Cellular Constructs. Journal of Dental Research (90): 456-462, 2011. Kinney JS, Morelli T, Braun T, Ramseier CA, Herr AE, Sugai JV, Shelburne CE,


Rayburn LA, Singh AK, Giannobile WV. Saliva/Pathogen Biomarker Signatures and Periodontal Disease Progression. Journal of Dental Research (90): 752-758, 2011. Bashutski JD, Eber R, Kinney J, Benavides E, Maitra S, Braun TM, Giannobile WV, McCauley LK. The Impact of Vitamin D Status on Periodontal Surgery Outcomes. Journal of Dental Research (90): 1007-1012, 2011. Braun TM and Alonzo TA. A+B+C Algorithmic Designs for Phase I Oncology Trials of Two-Agent Combinations. Clinical Trials (8): 247-259, 2011. Jia N, Braun TM. The Adaptive Accelerated Biased Coin Design for Phase I Clinical Trials. Journal of Applied Statistics (12): 2911–2924, 2011. Zhao L Lee J, Mody R, Braun TM. Demonstrating the Enhanced Performance of the Time-to-Event Continual Reassessment Method Relative to the Rolling Six Design for Use in Pediatric Oncology Phase I Trials. Clinical Trials (8): 361-369, 2011. Ferrara J, Harris A, Greenson J, Braun T, et al. Regenerating Islet-Derived 3α is a Biomarker of Gastrointestinal Graft-Versus-Host Disease. Blood (118): 6702-6708, 2011. Lee A, Bigelow-Ghaname C, Braun TM, Sugai JV, Teles RP, Loesche WJ, Kornman KS, Giannobile WV, Kinney JS. Bacterial and Salivary Biomarkers Predict the Gingival Inflammatory Profile. Journal of Periodontology (83): 79-89, 2012. Magenau J, Tobai H, Pawarode A, Braun T, et al. Clofarabine and Busulfan Conditioning Has Significant Activity in Non-Remission Acute Myelogenous Leukemia. Blood (118): 4258-4264, 2012. O’Kray H, Marshall TS, Braun TM. Supplementing Retention Through Crown/Preparation Modification: An In Vitro Study. Journal of Prosthetic Dentistry (107): 186-190, 2012. Harris AC, Ferrara JLM, Braun TM, et al. Plasma Biomarkers of Lower Gastrointestinal and Liver Acute Graft-Versus-Host Disease. Blood (119): 2960-2963, 2012. Yanik GA, Mineishi S, Levine JE, Kitko CL, White ES, Vander Lugt MT, Harris AC, Braun T, Cooke KR. Soluble Tumor Necrosis Factor Receptor: Enbrel (Entanercept) For Sub-Acute Pulmonary Dysfunction Following Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation (18): 1044-1054, 2012. Lee OE, Braun TM. Permutation Tests for Random Effects in Linear Mixed Models. Biometrics (68): 486-493, 2012. Westgate PM, Braun TM. The Effect Of Cluster Size Imbalance and Covariates on the Estimation Performance of QIF. Statistics in Medicine (20): 2209-2222, 2012. Choi SW, Stiff P, Cooke K, Ferrara JLM, Braun T, et al. TNF-inhibition with etanercept for graft versus host disease prevention in high risk HCT: Lower TNFR1 levels correlate with better outcomes. Biology of Blood and Marrow Transplantation


(18): 1525-1532, 2012. Zhang J, Braun TM, Taylor JMG. Adaptive Prior Variance Calibration in the Bayesian Continual Reassessment Method. Statistics in Medicine (32): 2221-2234, 2012. Harris AC, Kitko CL, Couriel DR, Braun TM, Choi SW, Magenau J, Mineishi S, Pawarode A, Yanik G, Levine JE. Extramedullary Relapse of Acute Myeloid Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors and Outcomes. Haematologica (98): 179-84, 2013. Kaigler D, Pagni G, Park CH, Braun T, Homan LA, Yi E, Tarle SA, Bartel RL, Giannobile WV. Stem Cell Therapy For Craniofacial Bone Regeneration: A Randomized, Controlled Feasibility Trial. Cell Transplantation (22): 767-777, 2013. Braun TM, Jia N. A Generalized Continual Reassessment Method for Two-Agent Phase I Trials. Statistics in Biopharmaceutical Research (5): 105-115, 2013. Lin AIC, Braun T, McNamara J, Gerstner GE. Esthetic Evaluation of Dynamic Smiles with Attention to Facial Muscle Activity. American Journal of Orthodontics and Dentofacial Orthopedics (143): 819-827, 2013. Westgate PM, Braun TM. An Improved Quadratic Inference Function for Parameter Estimation in the Analysis of Correlated Data. Statistics in Medicine (32): 3260-3273, 2013. Vander Lugt M, Braun TM, Hanash S, Ritz J, Ho VT, Antin JH, Zhang Q, Wong C-H, Wang H, Chin A, Gomez A, Harris AC, Levine JE, Choi SW, Couriel D, Reddy P, Ferrara JLM, Paczesny S. ST2 as a Marker for Risk of Therapy-Resistant Graft-Versus-Host Disease and Death. New England Journal of Medicine (369): 529-539, 2013. Zhang J, Braun TM. A Phase I Bayesian Adaptive Design to Simultaneously Optimize Dose and Schedule Assignments Both Among and Within Patients. Journal of the American Statistical Association (108): 892-901, 2013. Giannobile WV, Braun TM, Caplis AK, Doucette-Stamm L, Duff GW, and Kornman KS. Patient Stratification for Preventive Care in Dentistry. Journal of Dental Research (92): 694-701, 2013. Levine JE, Huber E, Hammer STG, Harris AC, Greenson JK, Braun TM, Ferrara JLM, Holler E. Low Paneth Cell Numbers at Onset of Gastrointestinal GVHD Identify Patients at High Risk for GVHD-Related Mortality. Blood (122): 1505-1509, 2013. Thall PF, Nguyen HQ, Braun TM, Qazilbash M. Using Joint Utilities of the Times to Response and Toxicity to Adaptively Optimize Schedule-Dose Regimes. Biometrics (69): 673–682, 2013

Tatarakis N, Kinney JS, Inglehart M, Braun TM, Shelburne C, Lang NP, Giannobile WV, Oh TJ. Clinical, Microbiological, and Salivary Biomarker Profiles of Dental Implant Patients with Type 2 Diabetes. Clinical Oral Implants Research (25): 803-812, 2014.


Shin W, Braun T, Inglehart M. Parents’ Dental Anxiety and Oral Health Literacy – Effects on Parents’ and Children’s Oral Health-related Experiences Parents’ Dental Anxiety and Oral Health Literacy – Effects on Parents’ and Children’s Oral Health-related Experiences. Journal of Public Health Dentistry (74): 195-201, 2014. Kinney JS, Morelli T, Oh M, Braun TM, CA Ramseier, Sugai JV, Giannobile WV. Crevicular Fluid Biomarkers and Periodontal Disease Progression. Journal of Clinical Periodontology (41): 113-120, 2014. Choi S, Braun T, Chang L, Ferrara J, Pawarode A, Magenau J, Hou G, Beumer J, Levine J, Couriel D, Krijanovski O, Kitko C, Yanik G, Lehmann M, Tawara I, Sun Y, Paczesny S, Mapara M, Dinarello C, DiPersio J, Reddy P. Vorinostat Plus Tacrolimus and Mycophenolate to Prevent Graft-Versus-Host Disease After Related-Donor Reduced-Intensity Conditioning Allogeneic Haemopoietic Stem-Cell Transplantation: a Phase ½ Trial. Lancet Oncology (15): 87-95, 2014. Kitko CL, Levine JE, Storer BE, Chai X, Fox DA, Braun TM, Martin PJ, Flowers ME, Hansen JA, Chang L, Conlon M, Fiema BJ, Morgan R, Pongtornpipat P, Lamiman K, Ferrara JLM, Lee SJ, Paczesny S. Plasma CXCL9 as an Onset Biomarker for Chronic GVHD. Blood (123): 786-793, 2014. Braun TM. The Current Design of Oncology Phase I Clinical Trials: Progressing From Algorithms to Statistical Models. Chinese Clinical Oncology 3(1): Article 2, 2014. Gerstner G, Madhavan S, Braun TM. Relationships Between Masticatory Rhymicity and Jaw Size During Development in Humans. Archives of Oral Biology (59): 711-721, 2014.

Aljateeli M, Koticha T, Bashutski J, Sugai JV, Braun TM, Giannobile, WV, Wang H-L. Surgical Periodontal Terapy with and without Initial Scaling and Root Planing in the Management of Chronic Periodontitis: A Randomized Clinical Trial. Journal of Clinical Periodontology (41): 693–700, 2014.

Levine JE, Braun TM, Harris AC, Holler E, Taylor A, Miller H, Magenau J, Weisdorf DJ, Ho VT, Bolaños-Meade J, Alousi, AU, Ferrara JLM. A Prognostic Score for Acute Graft-Versus-Host Disease Based on Biomarkers: A Multicenter Study. The Lancet – Haematology, (2): e21-e29, 2014. Choi S, Gatza E, Braun TM, Levine JE, Ferrara, JL, Zhao S, Wang T Chang L, Harris A, Pawarode A, Kitko C, Magenau JM, Yanik GA, Couriel DR, Goldstein S, Connelly J, Reddy P, and Paczesny S. Etanercept Plus Topical Corticosteroids as Initial Therapy for Grade 1 Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Cell Transplant. Biology of Blood and Marrow Transplantation (20): 1426-1434, 2014. Choi SW, Gleimer M, Li Y, Chang L, Paczesny S, Hanauer D, Frame D, Byersdorfer C, Reddy P, and Braun T. Baseline Body Mass Index Among Children and Adults Undergoing Allogeneic Hematopoietic Cell Transplantation: Clinical Characteristics and Outcomes. Bone Marrow Transplantation (50): 402-410, 2014. Reeves SL., Fullerton H, Cohn LM, Dombkowski K, Braun T, Boulton M, Lisabeth, L. The Role of Neighborhoods in the Receipt of Transcranial Doppler Screening


Among Children with Sickle Cell Disease. Journal of Pediatric Hematology/Oncology (37): 269-273, 2015. Boonstra PS, Shen J, Taylor JMG, Braun TM, Griffith KA, Daignault S, Kalemkerian GP, Theodore, Lawrence TS, and Schipper MJ. A Statistical Evaluation of Dose Expansion Cohorts in Phase I Clinical Trials. Journal of the National Cancer Institute (107): 1:6, 2015. Reeves SL, Fullerton H, Dombkowski K, Boulton M, Braun T, Lisabeth L. Physician Attitude, Awareness and Knowledge Regarding Guidelines for Transcranial Doppler Screening in Sickle Cell Disease. Clinical Pediatrics (54): 336–345, 2015. Braun TM, Doucette-Stamm L, Duff GS, Kornman KS, and Giannobile WV. Counterpoint: Risk Factors, Including Genetic Information, Add Value in Stratifying Patients for Optimal Preventive Dental Care. The Journal of the American Dental Association (146): 174-178, 2015. Abedin S, Yanik GA, Braun T, Pawarode A, Magenau J, Goldstein SC, Levine JE, Kitko CL, Couriel DR. Predictive value of bronchiolitis obliterans syndrome stage 0p in chronic graft-versus-host disease of the lung. Biol Blood Marrow Transplant (6): 1127-1131, 2015. Chen S and Braun TM. Tests for Time-Invariant Correlation of Longitudinally Measured Biomarkers. Statistics in Medicine (34): 3888-3900, 2015. Taichman LS, Inglehart MR, Giannobile W, Braun T, Kolenic G, Van Poznak C. Periodontal Health in Women with Early Stage Postmenopausal Breast Cancer Newly on Aromatase Inhibitors. Journal of Periodontology (86): 906-916, 2015. Magenau JM, Braun T, Reddy P, Parkin B, Pawarode A, Mineishi S, Choi S, Levine J, Li Y, Yanik G, Kitko C, Churay T, Frame D, Riwes MM, Harris A, Bixby D, Couriel DR, Goldstein SC. Allogeneic Transplantation with Myeloablative FluBu4 Conditioning Improves Survival Compared to Reduced Intensity FluBu2 Conditioning for Acute Myeloid Leukemia in Remission. Annals of Hematology (94): 1033-1041, 2015. Sun Z and Braun TM. A Two-Dimensional Biased Coin Design for Dual-Agent Dose-Finding Trials. Clinical Trials (12): 596-607, 2015.

Yaping S, Oravecz-Wilson K, Mathewson N, Wang Y, McEachin R, Liu C, Toubai T Wu J, Rossi C, Braun TM, Saunders T, Reddy P. Mature T Cell Responses Are Controlled By microRNA-142. Journal of Clinical Investigation (125): 2825–2840, 2015.

Dashow J, McHugh HB, Braun TM, Edwards SP, Helman JI, Brent WB. Significantly Decreased Recurrence Rates in Keratocystic Odontogenic Tumor With Simple Enucleation and Curettage Using Carnoy's Versus Modified Carnoy's Solution. Journal of Oral and Maxillofacial Surgery (73): 2132-2135, 2015. Kitko, C, Braun TM, Couriel DR, Choi SW, Goldstein S, Magenau J, Pawarode A, Reddy P, Schuler C, Yanik GA, Ferrara JL, Levine JE. Combination Therapy for GVHD Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a


Phase II Clinical Trial. Biology of Blood and Marrow Transplantation (22): 862-868, 2016. Pancer BA, Kott D, Sugai JV, Panagakos F, Braun TM, Teles RP, Giannobile WV, Kinney JS. Effects of Triclosan on Host Response and Microbial Biomarkers during Experimental Gingivitis. Journal of Clinical Periodontology (43): 435-444, 2016.

Song Y, Li Y, Braun TM, Magenau J, Parkin B, and Choi S. FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML. Bone Marrow Transplantation (51): 511-520, 2016. Braun TM, Kang S, Taylor JMG. A Phase I/II Trial Design when Response is Unobserved in Subjects with Dose-Limiting Toxicity. Statistical Methods in Medical Research (25): 659-673, 2016. Pawarode A, Mineishi S, Reddy P, Braun TM, Khaled YA, Choi SW, Magenau JM, Harris AC, Connelly JA, Kitko CL, Parkin BL, Goldstein SC, Yanik GA, Levine JE, Ferrara JL, Couriel DR. Reducing Treatment-related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series. Biology of Blood and Marrow Transplantation (22): 54-60, 2016. Petrie JG, Ohmit SE, Trucson R, Johnson E, Braun TM, Levine MZ, Eichelberger MC, Monto AS. Modest Waning of Influenza Vaccine Efficacy and Antibody Titers During the 2007-2008 Influenza Season. Journal of Infectious Diseases, 2016 (in press). Magenau J, Westervelt P, Khaled S, McGuirk J, Hari P, Eapen M, Becker PS, Parkin B, Braun T, Logan B, Wang H, Jagasia M, Rowley SD, Kim DH, Schechter T, Frey N, Scott B, Churay T, Lieland S, Forman S, Mineishi S. A Multicenter Trial of Myeloablative Clofarabine and Busulfan Conditioning for Relapsed or Primary Induction Failure Acute Myeloid Leukemia Not in Remission at Time of Allogeneic Hematopoietic Stem Cell Transplantation. Bone Marrow Transplantation, 2016 (in press).

PUBLICATIONS PENDING

Boonstra PS, Braun TM, Taylor JMG, Kidwell KM, Bellile EL, Daignault S, Zhao L, Griffith KA, Lawrence TS, Kalemkerian GP, and Schipper MJ. Building the Bridge to Phase II: Efficacy Estimation in Dose-Expansion Cohorts. (to be submitted to Journal of Clinical Oncology). Segal, B, Jiang H, and Braun T. Fast Approximation of Small p-values in Permutation Tests by Partitioning the Permutation Space. (under revision for Biometrics). Zhang Z, Sanchez B, Braun T, Peterson K, Hu H, Tellez-Rojo, MM. Extending Tests of Random Effects to Assess for Measurement Invariance in Factor Models. (to be submitted to Structural Equation Modeling). Henry NL, Braun T, Ali HY, Munir K, Silver SM, Gorski DH, Breslin TM, Griggs JJ. Use of the 21 Gene Recurrence Score Assay and Treatment-Decision Making in a Statewide Registry. (under review with Journal of Clinical Oncology).


Kim RY, Ward BB, Brockhoff HC, Helman JI, Braun TM, Skouteris CA. Correlation of Lymph Node Density With Negative Outcome Predictors in Oral and Maxillofacial Squamous Cell Carcinoma. (in revision for Journal of Oral and Maxillofacial Surgery).

CHAPTERS OF BOOKS Feng Z, Braun TM, McCulloch, C. Small Sample Inference for Clustered Data.

Proceedings of the Second Seattle Symposium in Biostatistics: Analysis of Correlated Data. Springer, 2005.

Braun TM, Thall, PF. Optimizing Schedule of Administration in Phase I Clinical Trials. Encyclopedia of Clinical Trials. Wiley, 2008.

Braun TM. Research Design and Biostatistical Considerations in Preclinical Research. Guidelines for Oral and Maxillofacial Regeneration. Quintessenz, 2011.

Braun TM, Thall, PF. Optimizing Schedule of Administration in Phase I Clinical Trials. Methods and Applications of Statistics in Clinical Trials. Wiley, 2013.

PATENTS (AUTHORS LISTED ALPHABETICALLY) Braun T, Giannobile W, Herr A, Shelburne C, Singh, AK. Multi-Analyte Analysis of

Saliva Biomarkers as Predictors of Periodontal and Peri-Implant Disease.

Braun T, Ferrara JLM, Hanash S, Levine J, Pacsezny S. Methods for Detecting Graft-Versus-Host Disease.

ACTIVE GRANTS See NIH Biosketch

COMPLETED GRANTS Title: Cellular and Molecular Studies in Bone Marrow Transplant

Funding Agency: National Institutes of Health PI: James Ferrara Award Amount: $9,190,324 Months Effort: 2.90 academic; 0.70 summer Role: Biostatistician Title: Periodontal Disease Prevention Study Funding Agency: Delta Dental PI: William Giannobile Award Amount: $408,595 Months Effort: 0.90 academic; 0.20 summer Role: Biostatistician Title: Statistical Methods and Issues for Implementing Adaptive Phase I Trials Funding Agency: National Institutes of Health PI: Thomas Braun Award Amount: $1,125,164 Months Effort: 1.80 academic; 0.40 summer


Role: Primary Investigator Title: Dental Utilization by Nursing Home Residents: 1986-2004 Funding Agency: National Institutes of Health PI: Barbara Smith Role: Co-Investigator Title: Two-Way Interrelationships: Periodontal Disease, Diabetes and Its Complications Funding Agency: National Institutes of Health PI: George Taylor Role: Biostatistician Title: SWAN Sleep Study II – Michigan Center Funding Agency: National Institutes of Health PI: Mary Fran Sowers Role: Biostatistician Title: Family Assessment of Risk Evaluation (FARE) Trial Funding Agency: Association of American Medical Colleges PI: Donald Nease Role: Biostatistician Title: Development of Oral Inflammatory Disease Model Relating Protein, Genetic, and Microbial Biomarkers Funding Agency: Colgate-Palmolive Company PI: Janet Kinney Role: Biostatistician Title: Impact of BRG1 Loss in Lung Cancer Development Funding Agency: National Institutes of Health PI: David Reisman Role: Biostatistician Title: Infliximab: A Pediatric Pharmacokinetic Study using Anti-Tumor Necrosis Factor Antibody (Infliximab) Funding Agency: Yale University PI: Gregory Yanik Role: Biostatistician Title: University of Michigan Core Clinical Center for the Bone Marrow Transplant (BMT) Research Network Funding Agency: National Institutes of Health PI: James Ferrara Role: Biostatistician Title: Proteome of Chronic Graft versus Host Disease Funding Agency: National Marrow Donor Program PI: Sophie Paczesny Award Amount: $68,515 Months Effort: 0.36 academic; 0.08 summer Role: Biostatistician


Title: Graft versus Host Disease Biomarkers: Prediction of Onset and Response to Therapy PI: Sophie Paczesny Award Amount: $999,999 Months Effort: 0.45 academic; 0.10 summer Role: Biostatistician Title: Hormone-Receptor-MMP Axis in Degenerative TMJ (Temporomandibular Joint) Disease Funding Agency: National Institutes of Health PI: Sunil Kapila Award Amount: $1,843,000 Months Effort: 0.45 academic; 0.10 summer Role: Biostatistician

Title: Phase II Study of a Novel GVHD Prevention Strategy: Etanercept and Photopheresis Funding Agency: National Institutes of Health PI: John Levine Award Amount: $515,800 Months Effort: 0.45 academic; 0.10 summer Role: Biostatistician Title: Serum Biomarkers for the Prediction of Graft-Versus-Host Disease in Children Funding Agency: Hyundai Hope on Wheels PI: John Levine Award Amount: $250,000 Months Effort: 0.18 academic; 0.04 summer Role: Biostatistician Title: Cellular and Molecular Studies in Bone Marrow Transplant Funding Agency: National Institutes of Health PI: James Ferrara Award Amount: $9,190,324.00 Months Effort: 0.45 academic; 0.10 summer Role: Biostatistician

Documents

THOMAS M. BRAUN - U-M School of Public Health · THOMAS M. BRAUN EDUCATION September 1996 – July 1999 University of Washington, Seattle, Washington Ph.D., Biostatistics